Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: yosi s who wrote (393)	1/4/1999 12:03:00 PM
From: BRAVEHEART	Read Replies (1) of 1386

Hi Yosi, Thanks for your efforts. What you describe is optimistic based on the existing shareprice. I like the late stage products. Could you clarify the following. "They expect tp sign a parnter for Phase 3 study with Dexanabinol and get payment from that. As for timing some time in the next month a short list should be form with final agreement 4-6 month from now. The market for HU 211 another name for Dexanabinol is over Big as for sales it will depend on pricing. ( They also have a third and final cohort of phase 2 that is 2/3 finished enrolment, so expect that data to be available late Q3 early Q4) right now no treatment exist. There are 350000 to 500,000 patients that will benefif for this indication in USA alone mostly car trauma, expect about same in Europe. So the market is from 750 million to 1.5 Billion is usa alone. Possible double that if it get Stroke indication. And double again when marketed in Europe." 1. The P-3 study for HU 211 is anticipated for what specific indication? 2. You mention a Stroke indication for Hu 211. Is there an existing trial for that indication or is it still in pre-clinical stages? 3. You mention European Markets. Are there trials in Europe for any specific indication? 4. What specific trial is this ? "( They also have a third and final cohort of phase 2 that is 2/3 finished enrolment, so expect that data to be available late Q3 early Q4)" 5. You say third and final. Assuming one was for TBI what indications are the other two for? I would imagine the company can be expected to draw down a little of the 10 million line of credit ( no big deal ). This is assuming things take longer than expected as is usual with biotec. It's good to know the line of credit is in place. Is there a floor to this conversion process? How much is remaining? Again the 10 million line of credit is encouraging. biz.yahoo.com Again I like the later stage products. The successful P-2 study for Hu-211 looks promising. biz.yahoo.com I also like the targeted markets. The low burn is surprising??? BEST WISHES LONE WOLF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next